The vicious circle of leptin and obesity

Current Nutrition and Food Science

Volumn 2, Issue 4, 2006, Pages 361-373

  Brito Díaz, Buenaventura ^a   del Cristo Rodriguez Perez M Maria ^a   Cabrera de León, Antonio ^b,c  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

^c San Juan de Dios Hospital   (Spain)

Author keywords

Leptin; Leptin resistance; Obesity

Indexed keywords

AGOUTI RELATED PROTEIN; CARNITINE PALMITOYLTRANSFERASE; FATTY ACID; GLUCOSE; ISOPROTEIN; JANUS KINASE 2; LEPTIN; LEPTIN RECEPTOR; NEUROPEPTIDE Y; OREXIN; PROOPIOMELANOCORTIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRIACYLGLYCEROL; UNCOUPLING PROTEIN 1; UNCOUPLING PROTEIN 2;

ADIPOCYTE; ADIPOSE TISSUE; ARCUATE NUCLEUS; BLOOD BRAIN BARRIER; BODY WEIGHT; CEREBROSPINAL FLUID; ENERGY BALANCE; ENERGY EXPENDITURE; FOOD DEPRIVATION; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HORMONE RESISTANCE; HORMONE TRANSPORT; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOTHALAMUS; HYPOTHALAMUS FUNCTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIPID DIET; LIPID METABOLISM; LIPID STORAGE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; STARVATION; THERMOGENESIS;

EID: 33750682649     PISSN: 15734013     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340106778699421     Document Type: Review

References (264)

1. Golay A, Masciangelo ML. Burden of obesity: from epidemic to costs. Rev Med Suisse 2005; 1: 807-10.
2. Olshansky SJ, Passaro DJ, Hershow RC, et al. A Potential Decline in Life Expectancy in the United. N Engl J Med 2005; 352: 1138-45.
3. Gregg EW, Cheng YJ, Cadwell BL, et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA 2005; 293: 1868-74.
4. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, Obesity, and Mortality from Cancer in a Prospectiveley Studied Cohort of U.S. Adults. N Engl J Med 2003; 348: 1625-38.
5. Zimmet P. Epidemiology of diabetes mellitus and associated cardiovascular risk factors: focus on human immunodeficiency virus and psychiatric disorders. Am J Med 2005; 118: 3S-8S.
6. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-32.
7. Chua SC Jr, Chung WK, Wu-Peng XS, et al. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 1996; 271: 994-96.
8. Murakami T, Yamashita T, Iida M, Kuwajima M, Shima K. Short form of leptin receptor performs signal transduction. Biochem Biophys Res Commun 1997; 231: 26-29.
9. Ahima RS, Flier J. Leptin. Annu Rev Physiol 2000; 62: 413-37.
10. Wauters M, Considine RV, Van Gaal LF. Human leptin: from an adipocyte hormone to an endocrine mediator. Eur J Endocrinol 2000; 143: 293-11.
11. Montague CT, Farooqi IS, Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387: 903-08.
12. Cusin I, Rohner-Jeanrenaud F, Stricker-Krongard A, Jeanrenaud B. The weight reducing effect of an intracerebroventricular bolus injection of leptin in genetically obese fa/fa rats: reduced sensivity compared with lean animals. Diabetes 1996; 45: 1446-50.
13. Wang T, Hartzell DL, Flatt WP, Martin RJ, Baile CA. Responses of lean and obese Zucker rats to centrally administered leptin. Physiol Behav 1998; 65: 333-41.
14. Seeley RJ, Van Dijk G, Campfield LA, et al. Intracerebroventricular leptin reduces food intake and body weight of lean rats but not obese Zucker rats Horm Metab Res 1996; 28: 664-68.
15. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein : evidence for a peripheral signal linking adiposity and central neural networks. Science 1995; 269: 546-49.
16. Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995; 269: 543-46.
17. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal weight and obese humans. N Engl J Med 1996; 334: 292-95.
18. Frederich RC, Harmann A, Anderson S, Looman B, Lowel BB, Flier JS. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med 1995; 1: 1155-61.
19. Halaas JL, Boozer C, Blair West J, Fidahusein N, Denton DA, Friedman JM. Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci USA 1997; 94: 8878-83.
20. Tartaglia LA. The leptin receptor. J Biol Chem 1997; 272: 6093-96.
21. Lammert A, Kiess W, Glasow A, Bottner A, Kratzsch J. Different isoforms of the soluble leptin receptor determine the leptin binding activity of human circulating blood. Biochem Biophys Res Commun 2001; 283: 982-88.
22. Friedman J, Halaas D. Leptin and the regulation of body composition. Nature 1998; 395: 763-70.
23. Reseland JE, Syversen U, Bakke I, et al. Leptin is expressed in and secreted from primary cultures of human osteoblasts and promotes bone mineralization. J Bone Miner Res 2001; 16: 1426-33.
24. Tartaglia LA, Dembski M, Weng X, et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995; 83: 1263-71.
25. Lee GH, Proenca R, Montez JM, et al. Abnormal splicing of the leptin receptor in diabetic mice. Nature 1996; 379: 632-35.
26. Bjorbaek C, Uotani S, da Silva B, Flier JS. Divergent signalling capacities of the long and short isoformas of the leptin receptor. J Biol Chem 1997; 272: 32686-95.
27. Baumann H, Morella KK, White DW, et al. The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors. Proc Natl Acad Sci USA 1996; 93: 8374-78.
28. Hakansson-Ovesjo ML, Collin M, Meister B. Down-regulated STAT3 messenger ribonucleic acid and STAT3 protein in the hypothalamic arcuate nucleus of the obese leptin-deficient (ob/ob) mouse. Endocrinology 2000; 141: 3946-55.
29. Chen H, Charlat O, Tartaglia LA, et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996; 84: 491-95.
30. Wang Z-W, Pan W-T, Lee Y, Kakuma T, Zhou Y-T, Unger RH. The role of leptin resistance in the lipid abnormalities of aging. FASEB J 2001; 15: 108-14.
31. Bates SH, Stearns WH, Dundon TA, et al. STAT3 signalling is required for leptin regulation of energy balance but not reproduction. Nature 2003; 421: 856-59.
32. Mckinley MJ, Oldfield BJ. The brain as an endocrine target for peptide hormones. Trends Endocrinol Metab 1998; 9: 389-53.
33. Weindl A. Neuroendocrine aspects of circumventricular organs. In: Ganong WF, Martini L, editors. Frontiers in neuroendocrinology. London: Oxford University Press, 1973; pp. 3-32.
34. Vaisse C, Halaas JL, Horvath CM, Darnell JE Jr, Stoffel M, Friedman JM. Leptin activation of STAT3 in the hypothalamus of wild type and ob/ob mice but not db/db mice. Nat Genet 1996; 14: 95-97.
35. Hakansson ML, Meister B. Transcription factor STAT3 in leptin target neurons of the rat hypothalamus. Neuroendocrinology 1998; 68: 420-27.
36. Hubschle T, Thom E, Watson A, Roth J, Klaus S, Meyerhof W. Leptin-induced nuclear translocation of STAT3 immunoreactivity in hypothalamic nuclei involved in body weight regulation. J Neurosci 2001; 21: 2413-24.
37. Stephens TW, Basinski M, Bristow PK, et al. The role of neuropeptide Y in the antiobesity action of obese gene product. Nature 1995; 377: 530-32.
38. Smith FJ, Campfield LA, Moschera JA, Bailon PS, Burn P. Feeding inhibition by neuropeptide Y. Nature 1996; 382: 307.
39. Schwartz MW, Seeley RJ,Camfield LA, Burn P, Baskin DB. Identification of targets of leptin action in the rat hypothalamus. J Clin Invest 1996; 98: 1101-06.
40. Kieffer TJ, Heller RS, Habener JF. Leptin receptors expressed on pancreatic beta-cells. Biochem. Biophys Res Commum 1996; 224: 522-27.
41. Zhou Y, Shimabukuro M, Wang M-Y, et al. Role of peroxisome proliferator-activated receptor alpha in disease of pancreatic beta cells. Proc Natl Acad Sci USA 1998; 95: 8898-03.
42. Zhou Y, Wang ZW, Higa M, Newgard CB, Unger RH. Reversing adipocyte differentiation: implications for treatment of obesity. Proc Natl Acad USA 1999; 96: 2391-95.
43. Kakuma T, Wang ZW, Pan W, Unger RH, Zhou Y-T. Role of leptin in peroxisome proliferator-activated receptor gamma coactivator-1 expression. Endocrinology 2000; 141: 4576-82.
44. Lee Y, Yu X, Gonzalez F, et al. PPAR alpha is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue. Proc Natl Acad Sci USA 2002; 99: 11848-53.
45. Unger RH, Zhou Y-T, Orci L. Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc Natl Acad Sci USA 1999; 96: 2327-32.
46. Pahan K, Sheikh FG, Khan M, Namboodiri AM, Singh I. Sphingomyelinase and ceramide stimulate the expression of inducible nitric-oxide synthase in rat primary astrocytes. J Biol Chem 1998; 273: 2591-00.
47. Shimabukuro M, Koyama K, Chen G, et al. Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci USA 1997; 94: 4637-41.
48. Lee Y, Hirose H, Zhou Y-T, Esser V, McGarry JD, Unger RH. Increased lipogenic capacity of the islets of obese rats: a role in the pathogenesis of NIDDM. Diabetes 1997; 46: 408-13.
49. Shimabukuro M, Higa M, Zhou YT, Wang MY, Newgard CB, Unger RH. Lipoapoptosis in Beta-cells of obese prediabeticf a/fa rats: role of serine palmitol transferase over-expression. J Biol Chem 1998; 273: 32487-90.
50. Obeid LM, Linardic CM, Karolak LA, Hannun YA. Programmed cell death induced by ceramide. Science 1993; 259: 1769-71.
51. DuBois RN, Gutpa N, Brockman J, Reddy BS, Krakow SL, Lazar MA. The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carcinogenesis 1998; 19: 49-53.
52. Unger RH. Leptin physiology: a second look. Regul Pep 2000; 92: 87-95.
53. Unger RH. Lipotoxic diseases. Annu Rev Med 2002; 53: 319-36.
54. Mantzoros CS, Flier JS, Rogol AD. A longitudinal assessment of hormonal and physical alterations during normal puberty in boys. Rising leptin levels may signal the onset of puberty. J Clin Endocrinol Metab 1997; 82: 1066-70.
55. Ahima RS, Dushay J, Flier SN, Prabakaran D, Flier J. Leptin accelerates the onset of puberty in normal female mice. J Clin Invest 1997; 99: 391-95.
56. Chehab FF, Lim ME, Lu R. Correction of the sterility defect in hozygous obese female mice by treatment with the human recombinant leptin. Nat Genet 1996; 12: 318-20.
57. Rosebaum M, Leibel RL. Leptin: a molecule integrating somatic energy stores, energy expenditure and fertility. Trend Endocrinol Metab 1998; 9: 117-24.
58. Clement K, Vaisse C, Lahlou S, et al. A mutation in human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998; 392: 398-401.
59. Strobel A, Issad T, Camoin L, Ozata M, Strosberg D. A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet 1998; 18: 213-15.
60. Cabrera de León A, González DA, Méndez LI, et al. Leptin and altitude in the cardiovascular-diseases. Obes Res 2004; 12: 1492-98.
61. Mecer JG, Hoggard N, Williams LM, Lawrence CB, Hannah LT, Tayhurn P. Localization of leptin receptor mRNA and the log form splice variant (Ob-Rb) in mouse hypothalamus and adjacent brain regions by in situ hybridization. FEBS Lett 1996; 387: 113-16.
62. Kutoh E, Boss O, Levasseur F, Giacobino JP. Quantification of the full-length leptin receptor (Ob-Rb) in human brawn and white adipose tissue. Life Sci 1998; 62: 445-51.
63. Buyse M, Ovesjo ML, Goiot H, et al. Expression and regulation of leptin receptor proteins in afferent and efferent neurons of the vagus nerve. Eur J Neurosci 2001; 14: 64-72.
64. Bazan JF. A novel family of growth factor receptors: a commun binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors and the p75 IL-2 receptor beta-chain. Biochem Biophys Res Commun 1989; 164: 788-95.
65. Hileman SM, Tornoe J, Flier JS, Bjorbaek C. Transcellular transport of leptin by the short leptin receptor isoform ObRa in Madin-Darby Canine Kidney cells. Endocrinology 2000; 141: 1955-61.
66. Heshka JT, Jones PJ. A role for dietary fat in leptin receptor, OB-Rb, function. Life Sci 2001; 69: 987-03.
67. Devos R, Guisez Y, Vander Heyden J, et al. Ligand independent dimerization of the extracellular comain of the leptin receptor and determination of the stoichiometry of the leptin binding. J Biol Chem 1997; 272: 18304-10.
68. Koistinen HA, Karonen SL, Livanaimen M, Koivisto VA. Circulatin leptin has saturable transport into intratecal space in humans. Eur J Clin Invest 1998; 28: 894-897.
69. Banks WA. Leptin transport across the blood-brain-barrier: implication for the cause and treatment of obesity. Curr Pharm Des 2001; 7: 125-33.
70. Maffei M, Halaas J, Ravussin E, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob-RNA in obese and weight-reduced subjects. Nat Med 1995; 1: 1155-61.
71. Schwartz MW, Peskind E, Raskind M, Boyko EJ, Porte Jr D. Cerebro-spinal fluid leptin levels: relationship to plasma levels and adiposity in human. Nat Med 1996; 2: 589-93.
72. Ghilardi N, Skoda RC. The leptin receptor activates janus kinase 2 and signals for proliferation in a factor dependent cell line. Mol Endocrinol 1997; 11: 393-99.
73. White DW, Kuropatwiski KK, Devos R, Baumann H, Tartaglia LA. Leptin receptor (OB-R) signalling. Cytoplasmic domain mutational analysis and evidence for receptor homooligomerization. J Biol Chem 1997; 272: 4065-71.
74. Chuan SC, Koutrs IK, Han L, et al. Fine structure of the murine leptin receptor gene: splice site suppression is required to form two alternatively spliced transcripts. Genomics 1997; 45: 264-70.
75. Kloek C, Haq AK, Dunn SL, Lavery HJ, Banks AS, Myers MG. Regulation of the Jak kinases by intracellular leptin receptor sequences. J Biol Chem 2002; 277: 41547-55.
76. Jiang N, He TC, Mijahima A, Wojchowski DM. The box 1 domain of the erythropoietin receptor specifies Janus kinase 2 activation and functions mitogenically within an interleukin 2 beta-receptor chimera. J Biol Chem 1996; 271: 16472-76.
77. Murakami M, Narazaki M, Hibi M, et al. Critical cytoplasmic region of the interleukin-6 signal transducer gp130 is conserved in the cytokine receptor family. Proc Natl Acad Sci USA 1991; 88: 11349-53.
78. Bahrenberg G, Behrmann I, Barthel A, et al. Identification of the critical sequence elements in the cytoplasmic domain of leptin receptor isoformas required for Janus/kinase-signal transducer and activator of transcription activation by receptor heterodimers. Mol Endocrinol 2002; 16: 859-72.
79. Goiot H, Attoub S, Kermorgant S, et al. Antral mucosa expresses functional leptin receptors coupled to STAT-3 signaling, which is involved in the control of gastric secretions in the rat. Gastroenterology 2001; 121: 1417-27.
80. Hamann A, Matthaei S. Regulation of energy balance by leptin. Exp Clin Endocrinol Diabetes 1996; 104: 293-00.
81. Sinha MK, Opentanova J, Ohannesian JP, et al. Evidence of free and bound leptin in human circulation. J Clin Invest 1996; 98: 1277-82.
82. Landt M. Leptin binding an binding capacity in serum. Clin Chem 2000; 46: 379-84.
83. Li C, Ioffe E, Fidahusein N, Connolly E, Friedman JM. Absence of soluble leptin receptor in plasma from dbPas/dbPas and other db/db mice. J Biol Chem 1998; 273: 10078-82.
84. Chan JL, Bluher S, Yiannakouris N, Suchard MA, Kratzsch J, Mantzoros Cs. Regulation of circulating soluble leptin receptor levels by gender, adiposity, sex steroids, and leptin: observational and interventional studies in humans. Diabetes 2002; 51: 2105-12.
85. Ogier V, Ziegler O, Mejean L, Nicolas JP, Stricker-Krongrad A. Obesity is associated with decreasing levels of the circulating soluble leptin receptor in humans. Int J Obes Relat Metab Disord 2002; 26: 496-503.
86. Kratzsch J, Lammert A, Bottner A, et al. Circulating soluble leptin receptor and free leptin index during childhood, puberty, and adolescence. J Clin Endocrinol Metab 2002; 87: 4587-94.
87. Carlsson LMS, Rowland AM, Clark RG, Gesundheit N, Wong WLT. Ligand mediated immunofunctional assay for quantification of growth hormone-binding protein in human blood. J Clin Endocrinol Metab 1991; 73: 1216-23.
88. Hahn T, Breininger J,Baskin D, SchWartz M. Coexpression of AGRPand NPY in fasting-activated hypothalamic neurons. Nat Neurosci 1998; 1: 271-72.
89. Broberger C, Johansen J, Johasson C, Schalling M, Hokfelt T. The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal, anoretic and monosodium glutamate-treated mice. Proc Natl Acad Sci USA 1998; 95: 15043-48.
90. Kristensen P, Judge ME, Thim L, et al. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 1998; 393: 72-76.
91. Elias CF, Lee C, Kelly J, Aschkenasi C, et al. Leptin activates hypothalamic CART neurons projecting to the spinal cord. Neuron 1998; 21: 1375-85.
92. Broadwell RD, Brightman MW. Entry of peroxidase into neurons of the central and peripheral nervous systems from extracerebral and cerebral blood. J Comp Neurol 1976; 166: 257-83.
93. Elmquist JK, Maratos-Flier E, Saper C, Flier J. Untraveling the central nervous system pathways underlying responses to leptin. Nat Neurosci 1998; 1: 445-50.
94. Elmquist JK, Bjorbaek C, Ahima RS, Flier JS, Saper CB. Distributions of leptin receptor mRNA isoformas in the rat brain. J Comp Neurol 1998; 395: 535-47.
95. Elmquist JK, Elias C, Saper C. From lesions to leptin: hypothalamic control of food intake and body weight. Neuron 1999; 22: 221-32.
96. Stellar E. The physiology of motivation. Psychol Rev 1954; 61: 5.
97. Meister B, Ceccatelli S, Hokfelt T, Anden NE, Anden M, Theodorsson E. Neurotransmitters, neuropeptides and binding sites in the rat mediobasal hypothalamus: effects of monosodium glutamate lesions. Exp Brain Res 1989; 76: 343-68.
98. Christope J. Is there appetite after GLP-1 and PACAP? Ann NY Acad Sci 1998; 865: 323-35.
99. Horvath TL, Diano S, van den Pol AN. Synaptic interaction between hypocretin (orexin) and neuropeptide Y cells in the rodent and primate hypothalamus: a novel circuit implicated in metabolic and endocrine regulations. J Neurosci 1999; 19: 1072-87.
100. Kalra SP, Dube MG, Fournier A, Kalra PS. Structure-function analysis of stimulation of food intake by neuropeptide Y: effects of receptor agonists. Physiol Behav 1991; 50: 05-09.
101. Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud F, Jeanrenaud B. Chronic intracerebroventricular neuropeptide Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology 1993; 133: 753-58.
102. Frankish HM, Dryden S, Hopkins D, Wang Q, Williams G. Neuropeptide Y, the hypothalamus and diabetes: insights into the central control of metabolism. Peptides 1995; 16: 757-71.
103. Kalra SP, Dube MG, Sahu A, Phelps CP, Kalra PS. Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food. Proc Natl Acad Sci USA 1991; 88: 10931-35.
104. Sahu A, Sninsky CA, Phelps CP, Dube MG, Kalra PS, Kalra SP. Neuropeptide Y release from the paraventricular nucleus increases in association with hyperphagia in streptozotocin-induced diabetic rats. Endocrinology 1992; 131: 2979-85.
105. Sahu A, Sninsky CA, Kalra SP. Evidence that hypothalamic neuropeptide Y gene expression and NPY levels in the paraventricular nucleus increase before the onset of hyperphagia in experimental diabetes. Brain Res 1997; 755: 339-42.
106. Fuxe K, Tinner B, Carbelotto L, Bunnemann B, Agnati LF. NPY Y1 receptor like immunoreactivity exists in a sub population of beta-endorphin immunoreactive nerve cells in the arcuate nucleus: a double immunolabelling analysis in the rat. Neurosci Lett 1997; 225: 49-52.
107. Bray GA, York DA. Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis. Physiol Rev 1979; 59: 719-09.
108. Jeanrenaud B, Cusin I, Rohner-Jeanrenaud F. From Claude Bernard to the regulatory system between the hypothalamus and the periphery: implications for homeostasis of body weight and obesity. C R Seances Soc Biol Fil 1998; 192: 829-41.
109. Iida M, Murakami T, Ishida K, Mizuno A, Kuwajima M, Shima K. Phenotype-linked amino acid alteration in leptin receptor cDNA from Zucker fatty (fa/fa) rat. Biochem Biophys Res Commun 1996; 222: 19-26.
110. Stanley BG, Daniel DR, Chin AS, Lebowitz SF. Paraventricular nucleus injections of peptide YY and neuropeptide Y preferentially enhance carbohydrate ingestion. Peptides 1985; 6: 1205-11.
111. Schwartz MW, Sipols AJ, Marks JL, et al. Inhibition of hypothalamic neuropeptide Y gene expression by insulin. Endocrinology 1992; 130: 3608-16.
112. Widdowson PS, Upton R, Henderson L, Buckingham R, Wilson S, Williams G. Reciprocal regional changes in brain NPY receptor density during dietary restriction and dietary-induced obesity in the rat. Brain Res 1997; 774: 1-10.
113. Williams G, Bing C, Cai XJ, Harrold JA, King PJ, Liu XH. The hypothalamus and the control of energy homeostasis. Different circuits, different purposes. Physiol Behav 2001; 74: 683-01.
114. Mountjoy K, Mortrud M, Low M, Simerly R, Cone R. Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol 1994; 8: 1298-08.
115. Roselli-Rehfuss L, Mountjoy KG, Robbins LS, et al. Identification of a receptor for gamma-melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. Proc Natl Acad Sci USA 1993; 90: 8856-60.
116. Harrold JA, Widdowson PS, Williams G. Altered energy balance causes selective changes in melanocortin-4 (MC4-R) but not melanocortin-3 (MC3-R) receptors in specific hypothalamic regions: further evidence that MC4-R activation is a physiological inhibitor of feeding. Diabetes 1999; 48: 267-71.
117. Huszar D, Lynch CA, Fairchild-Huntress V, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997; 88: 131-41.
118. Schioth HB, Muceniece R, Mutulis F, Bouifrouri AA, Mutule I, Wikberg JES. Further pharmacological characterisation of the selective melanocortin 4 receptor antagonist HS014: comparison with SHU9119. Neuropeptides 1999; 33: 191-96.
119. Benoit SC, Schwartz MW, Lachey JL, et al. A novel selective melanocortin-4 receptor agonist reduces food intake in rats and mice without producing aversion consequences. J Neurosci 2000; 20: 3442-48.
120. Cheung CC, Clifton DK, Steiner RA. Propiomelanocortin neurons are direct targets for leptin in the hypothalamus. Endocrinology 1997; 138: 4489-92.
121. Schwartz MW, Seeley RJ, Woods SC, Campfield LA, Burn P, Baskin DG. Leptin increases hypothalamic proopiomelanocortin mRNA expression in the rostral arcuate nucleus. Diabetes 1997; 46: 2119-23.
122. Mizuno TM, Kleopoulus SP, Bergen HT, Roberts JL, Priest CA, Mobbs CV. Hypothalamic pro-opiomelanocortin mRNA is reduced by fasting in ob/ob and db/db mice, but is stimulated by leptin. Diabetes 1998; 47: 294-97.
123. Seeley RJ, Yagaloff KA, Fisher SL, et al. Melanocortin receptors in leptin effects. Nature 1997; 390: 349.
124. Kask A, Rago L, Wikberg JE, Schioth HB. Evidence for involvement of the melanocortin MC4 receptor in the effects of leptin on food intake and body weight. Eur J Pharmacol 1998; 360: 15-19.
125. Satoh N, Ogawa Y, Katsuura G, et al. Satiety effect and sympathetic activation of leptin are mediated by hypothalamic melanocortin system. Neurosci Lett 1998; 249: 107-10.
126. Harrold JA, Williams G, Widdowson PS. Early leptin response to a palatable diet predicts dietary obesity in rats: key role of melanocortin-4 receptors in the ventromedial hypothalamic nucleus. J Neurochem 2000; 74: 1224-28.
127. Ebihara K, Ogawa Y, Katsuura G, et al. Involvement of agouti related protein an endogenous antagonist at the hypothalamic melanocortin receptor in leptin action. Diabetes 1999; 48: 2028-33.
128. Kaesterson RA, Huszar D, Lynch CA, Simerly RB, Cone RD. Induction of neuropeptide Y gene expression in the dorsal medial hypothalamic nucleus in two models of the agouti obesity syndrome. Mol Endocrinol 1997; 11: 630-37.
129. Kask A, Rago L, Korrovits P, Wikberg JE, Schioth HB. Evidence that orexigenic effects of melanocortin 4 receptor antagonist HSO14 are mediated by neuropeptide Y. Biochem Biophys Res Commun 1998; 248: 245-49.
130. Marsh DJ, Hollopeter G, Huszar D, et al. Response of melanocortin-4 receptor-deficient mice to anoretic and orexigenic peptides. Nat Genet 1999; 21: 119-22.
131. Haynes A, Jackson B, Overend P, et al. Effects of single and chronic intracerebroventricular administration of the orexins on feeding in the rat. Peptides 1999; 20: 1099-05.
132. Cai XJ, Denis R, Vernon RG, et al. Food restriction selectively increased hypothalamic orexin-B levels in lactating rats. Regul Pept 2001; 97: 163-68.
133. Hakansson M, De Lecea L, Sutcliffe JG, Yanagisawa M, Meister B. Leptin receptor and STAT immunoreactivities in hypocretin/orexin neurones of the lateral hypothaulamus. J Neuroendocrinol 1999; 11: 653-63.
134. Beck B, Richy S. Hypothalamic hypocretin/orexin and neuropeptide Y: divergent interaction with energy depletion and leptin. Biochem Biophys Res Commun 1999; 258: 119-22.
135. Cai XJ, Widdowson PS, Harrold J, el al. Hypothalamic orexin expression: modulation by blood glucose and feeding. Diabetes 1999; 48: 2132-37.
136. Griffond B, Risold PY, Jacquemard C, Colard C, Fellman D. Insulin-induced hypoglycemia increases preprohypocretin (orexin) mRNA in the rat lateral hypothalamic area. Neurosci Lett 1999; 262: 77-80.
137. Yamanaka A, Sakurai T, Katsumoto T, Yanagisawa M, Goto K. Chronic intracerebroventricular administration of orexin-A to rats increases food intake in daytime, but has no effect on body weight. Brain Res 1999; 849: 248-52.
138. Schwartz MW, Baskin DG, Kaiyala KJ, Woods SC. Model for the regulation of energy balance and adiposity by the central nervous system. Am J Clin Nutr 1999; 69: 584-96.
139. Yamamoto Y, Ueta Y, Date Y, et al. Down regulation of the prepro-orexin gene expresión in genetically obese mice. Mol Brain Res 1999; 65: 14-22.
140. Cai XJ, Carolyn AL, Buckinham RE, et al. Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and Zucker diabetic fatty rats and effects of rosiglitazone. Mol Brain Res 2000; 77: 131-37.
141. Pinto S, Roseberry AG, Liu H, et al. Rapid rewiring of arcuate nucleus feeding circuits by leptin. Science 2004; 304: 110-15.
142. Bouret SG, Draper SJ, Simerly RB. Trophic action of leptin on hypothalamic neurons that regulate feeding. Science 2004; 304: 108-10.
143. Elmquist JK, Flier JS. The fat-brain axis enters a new dimension. Science 2004; 304: 63-64.
144. Ahima RS, Bjorbaek C, Osei S, Flier JS. Regulation of neuronal and glial proteins by leptin: implications for brain development. Endocrinology 1999; 140: 2755-62.
145. Barker DJ. Fetal programming of coronary heart disease. Trends Endocrinol Metab 2002; 13: 364-68.
146. Koyama K, Chen G, Lee Y, Unger RH. Tissue triglycerides, insulin resistance, and insulin production: implications for hyperinsulinemia of obesity. Am J Physiol 1997; 273: E708-13.
147. Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, Unger RH. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci USA 1994; 91: 10878-82.
148. Orci L, Cook WS, Ravazzola M, et al. Rapid transformation of white adipocytes into fat-oxidizing machines. Proc Natl Acad Sci USA 2004; 101: 2058-63.
149. Zhou YT, Shimabukuro M, Koyama K, et al. Induction by leptin of uncoupling protein-2 and enzymes of fatty acid oxidation. Proc Natl Acad Sci USA 1997; 94: 6386-90.
150. Chen G, Koyama K, Yuan X, et al. Disappearance of body fat in normal rats induced by adenovirus-mediated leptin gene therapy. Proc Natl Acad Sci USA 1996; 93: 14795-99.
151. Rabinovitch A. Free radicals as mediators of pancreatic islet beta-cell injury in autoimmune diabetes. J Lab Clin Med 1992; 119: 455-56.
152. O'Rahilly S. Life without leptin. Nature 1998; 392: 330-31.
153. Lieber CS, Spritz N, DeCarli LM. Role of dietary, adipose, and endogenously synthesized fatty acids in the pathogenesis of the alcoholic fatty liver. J Clin Invest 1966; 45: 51-62.
154. Fontan A, Battin JJ, Kermarec J, Mortureux Y, Alberty J. Unusual forms of severe jaundice due to hepatitis: massive hepatic steatosis and renal tubular necrosis (Apropos of 2 cases). Arch Fr Pediatr 1965; 22: 1116-17.
155. Milburn JL Jr, Hirose H, Lee YH, et al. Pancreatic beta-cells in obesity. Evidence for induction of functional, morphologic, and metabolic abnormalities by increased long chain fatty acids. J Biol Chem 1995; 270: 1295-99.
156. Correa P. Comments on the epidemiology of large bowel cancer. Cancer Res 1975; 35: 3395-97.
157. Rashid A, Pizer ES, Moga M, et al. Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol 1997; 150: 201-08.
158. Saez E, Tontonoz P, Nelson MC, et al. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 1998; 4: 1058-61.
159. Lefebvre AM, Chen I, Desreumaux P, et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 1998; 4:1053-57.
160. Koyama K, Chen G, Wang MY, et al. Beta-cell function in normal rats made chronically hyperleptinemic by adenovirus-leptin gene therapy. Diabetes 1997; 46: 1276-80.
161. Osumi T, Wen JY, Hashimoto T. Two cis-acting regulatory sequences in the peroxisome proliferator-responsive enhancer region of rat acyl-CoA oxidase gene. Biochem Biophys Res Commun 1991; 175: 866-71.
162. Mascaro C, Acosta E, Ortiz JA, Marrero PF, Hegardt FG, Hato D. Control of human muscle-type carnitine pahmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor. J Biol Chem 1998; 273: 8560-63.
163. Fleury C, Neverova M, Collins S, et al. Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nat Genet 1997; 15: 269-72.
164. Iida M, Murakami T, Ishida K, Mizuno A, Kuwajima M, Shima K. Substitution at codon 269 (glutamine - > proline) of the leptin receptor (OB-R) cDNA is the only mutation found in the Zucker fatty (fa /fa) rat. Biochem Biophys Res Commun. 1996; 224: 597-04.
165. Caro JF, Kolaczynski JW, Nyce MR, et al. Decreased cerebrospinal-fluid/ serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 1996; 348: 159-61.
166. Van Heek M, Compton DS, France CF, et al. Diet induced obese mice develop peripheral but not central resistance to leptin. J Clin Invest 1997; 99: 385-90.
167. Hileman SM, Pierroz DD, Masuzaki H, et al. Characterization of short isoformas of the leptin receptor in rat cerebral microvessels and brain uptake of leptin in mouse models of obesity. Endocrinology 2002; 143: 775-83.
168. Wilsey J, Zolotukhin S, Prima V, Scarpace PJ. Central leptin gene therapy fails to overcome leptin resistance associated with diet-induced obesity. Am J Physiol 2003; 285: R1011-R20.
169. Banks WA, Kastin AJ, Huang W, Jaspan JB, Maness LM. Leptin transport across the blood-brain-barrier of the Koletsky rat is not mediated by a product of the leptin receptor gene. Brain Res 2002; 950: 130-36.
170. Burguera B, Couce ME, Curran GL, et al. Obesity is associated with a decresed leptin transport across the blood-brain barrier in rats. Diabetes 2000; 49: 1219-23.
171. Dube MG, Kalra SP, Kalra PS. Hypothalamic galanin is upregulated during hyperphagia and increased body weight gain induced by disruption of signalling in the ventromedial nucleus. Peptides 2000; 21: 519-26.
172. Kastin AJ, Pan W, Maness LM, Koletsky RJ, Ernsberguer P. Decreased transport of leptin across the blood-brain barrier inrats lacking the short form of the leptin receptor. Peptides 1999; 20: 1449-53.
173. Banks WA, Kastin AJ, Huang W, Jaspan JB, Manes LM. Leptin enters the brain by a saturable system independent of insulin. Peptides 1996; 17: 305-11
174. Banks WA, Farrell CL. Impaired transport of leptin across the blood-brain barrier in obesity is adquired and reversible. Am J Physiol Endocrinol Metab 2003; 285: E10-E15.
175. Banks WA, Coon AB, Robinson SM, et al. Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes 2004; 53: 1253-58.
176. Neel JV. Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? Am J Hum Genet 1962; 14: 353-62.
177. Kelley DE, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance. Diabetes 2000; 49: 677-83.
178. Laybutt DR, Schmitz-Peiffer S, Ruderman NB, Chisholm D, Biden T, Kraegen EW. Activation of protein kinase-C-epsilon may contribute to muscle insulin resistance induced by lipid accumulation during chronic glucose infusion in rats (Abstract). Diabetes 1997; 46: 241A.
179. Donnelly R, Reed MJ, Azhar S, Reaven GM. Expression of the major isoenzyme of protein kinase C in skeletal muscle, nPKC theta, varies with muscle type and in response to fructose-induced insulin resistance. Endocrinology 1994; 135: 2369-74.
180. Muller HK, Kellerer M, Ermel B, et al. Prevention by protein kinase C inhibitors of glucose-induced insulin-receptor tyrosine kinase resistance in fat cells. Diabetes 1991; 40: 1440-48.
181. Schmitz-Peiffer C, Oakes ND, Browne CI, Kraegen EW, Biden TJ. Reversal of chronic alterations of skeletal muscle protein kinase-C from fat-fed rats by BRL-49653. Am J Physiol 1997; 273: E915-21.
182. Schmitz-Peiffer C, Craig DL, Biden TJ. Ceramide generation is sufficient to account for the inhibition of the insulin stimulated PKB pathway in C2C12 skeletal muscle cells preteated with palmitate. J Biol Chem 1999; 274: 24202-10.
183. Dresner A, Laurent D, Marcucci M, et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidyl-inositol 3-kinase activity. J Clin Invest 1999; 103: 253-59.
184. Nam S-Y, Kratzsch J, Kim KW, Kim KR, Lim S-K, Marcus C. Cerebrospinal fluid and plasma concentrations of leptin, NPY, and alfa-MSH in obese women and their relationship to negative energy balance. J Clin Endocrinol Metab 2001; 86: 4849-53.
185. Shek EW, Scarpace PJ. Resistance to the anorexic, and thermogenic effects of centrally administrated leptin in obese aged rats. Regul Peptide 2000; 92: 65-71.
186. Widdowson PS, Upton R, Buckingham R, Arch J, Williams G. Inhibition of food response to intracerebroventricular injection of leptin is attenuated in rats with diet-induced obesity. Diabetes 1997; 46: 1782-85.
187. Levin BE, Dunn-Meynell AA. Reduced central leptin sensivity in rats with diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 2002; 283: R941-48.
188. Pal R, Sahu A. Leptin signalling in the hypothalamus during chronic central leptin infusion. Endocrinology 2003; 144: 3789-98.
189. Sahu A. Resistance to the saciety action of leptin following chronic central leptin infusion is associated with the development of leptin resistance in neuropeptide Y. J Neuroendocrinol 2002; 14: 796-04.
190. Bjorbaek C, Elinquist JK, Frantz JD, Shoelson SE, Flier JS. Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol Cell 1998; 1: 619-25.
191. Endo TA, Masuhara M, Yokouchi M, et al. A new protein containing an SH-2 domain that inhibits Jak kinases. Nature 1997; 387: 921-24.
192. Starr R, Willson TA, Viney EM, et al. A family of cytokine-inducible inhibition of signalling. Nature 1997; 387: 917-21.
193. Naka t, Narazaki M, Hirata M, et al. Structure and function of a new STAT-induced STAT ihibitor. Nature 1997; 387: 924-29.
194. Kulkami RN, Wang ZL, Wang RM, et al. Leptin rapidly suppresses insulin release from insulinoma cells, rat and human islets and, in vivo, in mice. J Clin Invest 1997; 100: 2729-36.
195. Lin S, Thomas TC, Storlien LH, Huang XF. Development of high fat diet induced obesity and leptin resistence in C57B1/6J mice. Int J Obes 2000; 24: 01-08.
196. Surwit RS, Petro AE, Parek P, Collins S. Low plasma leptin in response to dietary fat in diabetes and obesity prone mice. Diabetes 1997; 46: 1516-20.
197. Boado RJ, Golden PL, Levin N, Pardridge WM. Up regulation of blood-brain barrier short-form leptin receptor gene products in rats fed a high fat diet. J Neurochem 1998; 71: 1761-64.
198. Schwartz MW, Baskin DO, Bukowski TF, et al. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes 1996; 45: 531-35.
199. Lin S, Storlien LH, Huang XF. Leptin receptor, NPY, POMC mRNA expression in the diet-induced obese mouse brain. Brain Res 2000; 875: 89-95.
200. Roden M, Price TB, Perseghin G, et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996; 97: 2859-65.
201. Storlein L, Jenkins A, Chisholm D, Pascoe W, Khouri S, Kraegen E. Influence of dietary fat composition on development of insulin resistance in rats: relationship to muscle triglicerides and w3 fatty acids in muscle phospholipid. Diabetes 1991; 40: 280-89.
202. Felber J-P, Ferrannini E, Golay A, et al. Role of lipid oxidation in the pathogenesis of insulin resistance of obesity and type II diabetes. Diabetes 1987; 36: 1341-50.
203. Jones CN, Abbasi F, Carantoni M, Polonsky KS, Reaven GM. Roles of insulin resistance and obesity in regulation of plasma insulin concentrations. Am J Physiol Endocrinol Metab 2000; 278: E501-08.
204. Rizvi AA. Metabolic markers of insulin resistance in overweight persons. Ann Intern Med 2004; 141: 243; author reply 243-44.
205. Nestel P. Metabolic complications of obesity. Asia Pac J Clin Nutr 2004; 13: S35.
206. Lara-Castro C, Garvey WT. Diet, insulin resistance and obesity: zoning in on data for Atkins dieters living in South Beach. J Clin Endocrinol Metab 2004; 89: 4197-05.
207. Kim SH, Abbasi F, Reaven GM. Impact of degree of obesity on surrogate estimates of insulin resistance. Diabetes Care 2004; 27: 1998-02.
208. Reaven GM, Moore J, Greenfield M. Quantification of insulin secretion and in vivo insulin action in nonobese and moderately obese individuals with normal glucose tolerance. Diabetes 1983; 32: 600-04.
209. Polonsky KS, Given BD, Hirsch L, et al. Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest 1998; 81: 435-41.
210. Sharma AM, Chetty VT. Obesity, hypertension and insulin resistance. Acta Diabetol 2005; 42: S03-08.
211. Bonora E, Zavaroni I, Bruschi F, et al. Peripheral hyperinsulinemia of simple obesity: pancreatic hypersecretion or impaires insulin metabolism? J Clin Endocrinol Metab 1984; 59: 1121-27.
212. Flack JM, Sowers JR. Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia. Am J Med 1991; 91: S11-21.
213. Reaven GM. Compensatory hyperinsulinemia and the development of an atherogenic lipoprotein profile: the price paid to maintain glucose homeostasis in insulin-reistant individuals. Endocrinol Metab Clin North Am 2005; 34: 49-62.
214. Bioletto S, Golay A, Munger R, Kalix B, James RW. Acute hyperinsulinemia and very-low density and low density lipoprotein subfractions in obese subjects. Am J Clin Nutr 2000; 71: 443-49.
215. DeFronzo RA. Insulin resistance, hyperinsulinemia and coronary artery disease: a complex metabolic web. J Cardiovasc Pharmacol 1992; 20: S1-16.
216. Agata J, Miyazaki Y, Takada M, et al. Association of insulin resistance and hyperinsulinemia with disturbed lipid metabolism in patients with essential hypertension. Hypertens Res 1998; 21: 57-62.
217. Reaven GM. The role of insulin resistance and hyperinsulinemia in coronary heart disease. Metabolism 1992; 41: 16-19.
218. Meigs JB, Muller DC, Nathan DM, Blake DR, Andres R: Baltimore Longitudinal Study of Aging. The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging. Diabetes 2003; 52: 1475-84.
219. Carnevale Schianca GP, Rossi A, Sainaghi PP, Maduli E, Bartoli E. The significance of impaired fasting glucose versus impaired glucose tolerance: importance of insulin secretion and resistance. Diabetes Care 2003; 26: 1333-37.
220. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002; 19: 708-23.
221. Gomez-Diaz R, Aguilar-Salinas CA, Moran Villota S, et al. Lack of agreement between the revised criteria of impaired fasting glucose and impaired glucose tolerance in children with excess body weight. Diabetes Care 2004; 27: 2229-33.
222. Jermendy G, Hidvegi T, Hetyesi K, Biro L. Is it time to use the new lower limit of impaired fasting glucose (IFG) among the ATPIII criteria for diagnosis of the metabolic syndrome? Prevalence rate of the metabolic syndrome using old new lower limits of IFG in obese and/or hypertensive subjects. Diabetes Nutr Metab 2004; 17: 169-70.
223. Borch-Johnsen K, Colagiuri S, Balkau B, et al. Creating a pandemia of prediabetes: The proposed new diagnostic criteria for impaired fasting glycaemia. Diabetologia 2004; 47: 1396-02.
224. Kriketos A, Milner KL, Denyer G, Campbell L. Is postprandial hypertriglyceridaemia in relatives of type 2 diabetic subjects a consequence of insulin resistance? Eur J Clin Invest 2005; 35: 117-25.
225. Jeusette IC, Lhoest ET, Istasse LP, Diez MO. Influence of obesity on plasma lipid and lipoprotein concentrations in dogs. Am J Vet Res 2005; 66: 81-86.
226. Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 2004; 89: 2601-07.
227. Cziraky MJ. Management of dyslipidemia in patients with metabolic syndrome. J Am Pharm Assoc (Wash DC) 2004; 44: 478-88.
228. Steinmetz A, Schafer JR. Secondary disorders of lipid metabolism, metabolic syndrome and familial combined hyperlipidemia] Wien Med Wochenschr 1994; 144: 299-07.
229. Ruotolo G, Howard BV. Dyslipidemia of the metabolic syndrome. Curr Cardiol Rep 2002; 4: 494-00.
230. Kuzuya T, Nakagawa S, Satoh J, et al. Committee of the Japan Diabetes Society on the diagnosis criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract 2002; 55: 65-85.
231. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-97.
232. Sundell J. Obesity and diabetes as risk factors for coronary artery disease: from the epidemiological aspect to the initial vascular mechanisms. Diabetes Obes Metab 2005; 7: 9-20.
233. Muhammad S. Epidemiology of diabetes and obesity in the United States. Compend Contin Educ Dent 2004; 25: 195-98, 00, 02; quiz 04.
234. Lazar MA. How obesity causes diabetes: not a tall tale. Science 2005; 307: 373-75.
235. Rhodes CJ. Type 2 diabetes-a matter of beta-cell life and death? Science 2005; 307: 380-84.
236. Unger RH, Orci L. Lipoapoptosis: its mechanism and its diseases. Biochim Biophys Acta 2002; 1585: 202-12.
237. Eitel K, Staiger H, Brendel MD, et al. Different role of saturated and unsaturated fatty acids in beta-cell apoptosis. Biochem Biophys Res Commun 2002; 299: 853-56.
238. Unger RH, Zhou YT. Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes 2001; 50: S118-21.
239. Higa M, Zhou YT, Ravazzola M, Baetens D, Orci L, Unger RH. Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci USA 1999; 96: 11513-18.
240. Shimabukuro M, Wang MY, Zhou YT, Newgard CB, Unger RH. Protection against lipoapoptosis of beta cells through leptin-dependent maintenance of Bcl-2-expression. Proc Natl Acad Sci USA 1998; 95: 9558-61.
241. Shankar SS, Steinberg HO. FFAs: do they play a role in vascular disease in the insulin resistance syndrome? Curr Diab Rep 2005; 5: 30-35.
242. Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 2004; 44: 2293-00.
243. Sjoholm A, Nystrom T. Endothelial inflammation in insulin resistance. Lancet 2005; 365: 610-12.
244. Lamharzi N, Renard CB, Kramer F, et al. Hyperlipidemia in concert with hyperglycemia stimulates the proliferation of macrophages in atherosclerotic lesions: potential role of glucose-oxidized LDL. Diabetes 2004; 53: 3217-25.
245. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004; 63: 582-92.
246. Simon K. Clinical significance of blood glucose levels in the pathogenesis of-(atherosclerotic)-macroangiopathy. Orv Hetil 2004; 145: 861-66.
247. Death AK, Fisher EJ, McGrath KC, et al. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in-diabetes. Atherosclerosis 2003; 168: 263-69.
248. Morricone L, Donati C, Hassan T, Cioffi P, Caviezel F. Relationship of visceral fat distribution to angiographically assessed coronary artery disease: results in subjects with or without diabetes or impaired glucose tolerance. Nutr Metab Cardiovasc Dis 2002; 12: 275-83.
249. Cnop M, Hannaert JC, Hoorens A, Eizirik DL, Pipeleers DG. Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation. Diabetes 2001; 50: 1771-77.
250. Lupi R, Dotta F, Marselli L, et al. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2regulated. Diabetes 2002; 51: 1437-42.
251. Dyntar D, Eppenberger-Eberhardt M, Maedler K, et al. Glucose and palmitic acid induce degeneration of myofibrils and modulate apoptosis-in-ratadult-cardiomyocytes. Diabetes 2001; 50: 2105-13.
252. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005; 96: 939-49.
253. Calderon KS, Yucha CB, Schaffer SD. Obesity-related cardiovascular risk factors: intervention recommendations to decrease adolescent obesity. J Pediatr Nurs 2005; 20: 3-14.
254. Reeder BA, Angel A, Ledoux M, Rabkin SW, Young TK, Sweet LE. Obesity and its relation to cardiovascular disease risk factors in Canadian adults. Canadian Heart Health Surveys Research Group. CMAJ 1992; 146: 2009-19.
255. Thomas GN, Ho SY, Lam KS, Janus ED, Hedley AJ, Lam TH: Hong Kong Cardiovascular Risk Factor Prevalence Study Steering Committee. Impact of obesity and body fat distribution on cardiovascular risk factors in Hong Kong Chinese. Obes Res 2004; 12: 1805-13.
256. Tanaka S, Togashi K, Rankinen T, et al. Is adiposity at normal body weight relevant for cardiovascular disease risk?. Int J Obes Relat Metab Disord 2002; 26: 176-83.
257. Scaglione R, Argano C, Di Chiara T, Licata G. Obesity and cardiovascular risk: the new public health problem of worldwide proportions. Expert Rev Cardiovasc Ther 2004; 2: 203-12.
258. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
259. Zieve FJ. The metabolic syndrome: diagnosis and treatment. Clin Cornerstone 2004; 6: S5-13.
260. Wyszynski DF, Waterworth DM, Barter PJ, et al. Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). Am J Cardiol 2005; 95: 194-98.
261. Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES. Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 2004; 53: 1195-00.
262. Alvarez Cosmea A, Lopez Fernandez V, Suarez Garcia S, Arias Garcia T, Prieto Diaz MA, Diaz Gonzalez L. Differences in the prevalence of metabolic syndrome according to the ATP-III and WHO definitions. Med Clin (Barc) 2005; 124: 368-70.
263. Thomas GN, Ho SY, Janus ED, Lam KS, Hedley AJ, Lam TH: Hong Kong Cardiovascular Risk Factor Prevalence Study Steering Committee. The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) prevalence of the metabolic syndrome in a Chinese population. Diabetes Res Clin Pract 2005; 67: 251-57.
264. Kohler HP. Insulin resistance syndrome: interaction with coagulation and fibrinolysis. Swiss Med Wkly 2002; 132: 241-52.